Figure 1
Figure 1. Myosin-IIA inhibition of MKs enhances generation of fragments that are similar in size to normal human pre/proplatelets. (A) Platelet generation scheme: MKs in bone marrow extend membrane processes into the flowing blood where shear stress fragments large pre/proplatelets. Conversion to dumbbell-shaped proplatelets allows fission to small, normal platelets. (B) MKs enriched from fresh human bone marrow were stained with Hoechst 33342 and anti-CD41 and treated ± blebbistatin before micropipette aspiration. Fragmentation occurs within seconds and persists for minutes (scale bar = 10 μm). (C) Blebbistatin enhances fragment frequency and results in a higher percentage of total MK volume release vs DMSO control (N = 4 cells, n > 10 fragments/cell for control, n > 30 fragments/cell for blebb, ± standard error of the mean (SEM), *P < .01). The single-parameter fit goes through both data points. (D) Released fragment size is unaffected by blebbistatin, and fragments are similar in size to normal human pre/proplatelets (n = 35 fragments for control, n = 135 fragments for blebb, ±SEM, P = .5). The pink shaded region denotes the calculated range of projected area from normal human platelet diameters. The gray shaded region denotes estimations from reported preplatelet diameters.2 (E) MEG-01 cells nucleofected with GFP-MIIA and treated ± blebbistatin and fluorescent images of GFP-MIIA MEG-01 cells undergoing fragmentation in micropipette aspiration (scale bar = 10 μm). Intensity of cell body has been adjusted to allow visualization of aspirated fragment. Intensity is plotted below each micrograph. (F) Blebbistatin treatment of non-nucleofected MEG-01 cells increases the number of fragments per cell as well as permission of fragmentation at smaller-radius pipettes. Linear fit of DMSO: y = 0.57x − 0.8, R2 = 0.99, n = 2, ±SEM. 20 μM blebbistatin: n > 15 ±SEM. Statistical significance determined between DMSO and 20 μM blebbistatin for a given Rp, *P < .05. (G) The fragment area is not affected by blebbistatin, but treatment facilitates fragmentation of smaller fragments from smaller pipettes. Linear fit of 20 μM blebbistatin: y = 138x−187 (R2 = 0.99, n < 40, ±SEM). DMSO: n > 6 ±SEM. The pink shaded region denotes calculated range of area from reported normal human platelet diameters. The gray shaded region denotes estimations from reported preplatelet diameters.2

Myosin-IIA inhibition of MKs enhances generation of fragments that are similar in size to normal human pre/proplatelets. (A) Platelet generation scheme: MKs in bone marrow extend membrane processes into the flowing blood where shear stress fragments large pre/proplatelets. Conversion to dumbbell-shaped proplatelets allows fission to small, normal platelets. (B) MKs enriched from fresh human bone marrow were stained with Hoechst 33342 and anti-CD41 and treated ± blebbistatin before micropipette aspiration. Fragmentation occurs within seconds and persists for minutes (scale bar = 10 μm). (C) Blebbistatin enhances fragment frequency and results in a higher percentage of total MK volume release vs DMSO control (N = 4 cells, n > 10 fragments/cell for control, n > 30 fragments/cell for blebb, ± standard error of the mean (SEM), *P < .01). The single-parameter fit goes through both data points. (D) Released fragment size is unaffected by blebbistatin, and fragments are similar in size to normal human pre/proplatelets (n = 35 fragments for control, n = 135 fragments for blebb, ±SEM, P = .5). The pink shaded region denotes the calculated range of projected area from normal human platelet diameters. The gray shaded region denotes estimations from reported preplatelet diameters. (E) MEG-01 cells nucleofected with GFP-MIIA and treated ± blebbistatin and fluorescent images of GFP-MIIA MEG-01 cells undergoing fragmentation in micropipette aspiration (scale bar = 10 μm). Intensity of cell body has been adjusted to allow visualization of aspirated fragment. Intensity is plotted below each micrograph. (F) Blebbistatin treatment of non-nucleofected MEG-01 cells increases the number of fragments per cell as well as permission of fragmentation at smaller-radius pipettes. Linear fit of DMSO: y = 0.57x − 0.8, R2 = 0.99, n = 2, ±SEM. 20 μM blebbistatin: n > 15 ±SEM. Statistical significance determined between DMSO and 20 μM blebbistatin for a given Rp, *P < .05. (G) The fragment area is not affected by blebbistatin, but treatment facilitates fragmentation of smaller fragments from smaller pipettes. Linear fit of 20 μM blebbistatin: y = 138x−187 (R2 = 0.99, n < 40, ±SEM). DMSO: n > 6 ±SEM. The pink shaded region denotes calculated range of area from reported normal human platelet diameters. The gray shaded region denotes estimations from reported preplatelet diameters.

Close Modal

or Create an Account

Close Modal
Close Modal